Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04637620
PHASE2

NMDA Modulation in Major Depressive Disorder

Sponsor: China Medical University Hospital

View on ClinicalTrials.gov

Summary

Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of an NMDA enhancer (NMDAE) in the treatment of MDD in the adults.

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2017-06-01

Completion Date

2026-12

Last Updated

2025-02-19

Healthy Volunteers

No

Interventions

DRUG

NMDAE

Use of an NMDA enhancer for the treatment of MDD

DRUG

Sertraline

Use of SSRI as an active comparator

DRUG

Placebo Cap

Use of placebo as a comparator

Locations (1)

Department of Psychiatry, China Medical University Hospital

Taichung, Taiwan